Clinical Research Directory
Browse clinical research sites, groups, and studies.
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
Sponsor: BioPorto Diagnostics
Summary
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Official title: Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults (EPACRA-AKI)
Key Details
Gender
All
Age Range
22 Years - Any
Study Type
OBSERVATIONAL
Enrollment
800
Start Date
2024-10-28
Completion Date
2026-01-31
Last Updated
2025-11-19
Healthy Volunteers
No
Conditions
Interventions
ProNephro AKI (NGAL)
ProNephro AKI™ (NGAL) is an immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine.
Locations (12)
The University of Alabama
Birmingham, Alabama, United States
UC Davis
Sacramento, California, United States
Yale University
New Haven, Connecticut, United States
University of Chicago
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
University of New Mexico
Albuquerque, New Mexico, United States
Columbia University
New York, New York, United States
Wake Forest University
Winston-Salem, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Medical University of South Carolina
Charleston, South Carolina, United States